Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: SnakeInATuxedo who wrote (2330)	6/28/1999 1:09:00 PM
From: Walter Morton	Respond to of 2742

Would you want this company to be your new stock: finance.yahoo.com

To: SnakeInATuxedo who wrote (2330)	3/17/2000 11:06:00 AM
From: Walter Morton	Respond to of 2742

----- Original Message ----- From: Herman F. Staats, Ph.D. To: Walter Morton Sent: Friday, March 17, 2000 7:14 AM Subject: Re: Clarification Walter: The peptide immunogen has been tested in mice, guinea pigs, monkeys and humans. The nasal immunization strategies have only been tested in mice. We are planning nasal immuniation studies using the peptide + cytokines as adjuvants for non-human primates. Herman At 02:15 AM 3/17/00 -0500, you wrote: Thank you. I read the attached October 19, 1999 article released by Duke University, "DUKE TEAM SEEKS NOVEL VACCINE STRATEGY FOR HIV." It's very interesting. Have you begun testing the vaccine in small mammals or have you already moved on to testing in non-human primates? Thanks, Walter Morton